淋巴结SUVmax提升PSMA-PET/CT在中高危前列腺癌中的淋巴结分期效能
这项国际多中心研究纳入521例病理确诊前列腺癌患者,评估淋巴结SUVmax能否提升PSMA-PET/CT检测淋巴结侵犯的阳性预测值。结果显示,PSMA-PET对淋巴结侵犯的灵敏度45.0%、特异度94.3%、阳性预测值64.7%、阴性预测值88.3%;加入淋巴结SUVmax≥4.9后阳性预测值升至81.1%、灵敏度升至71.4%。结合PSA、MRI T分期和miT分期构建的决策工具可识别95%的高危组pN1病例。
要点
- PSMA-PET/CT检测淋巴结侵犯的阳性预测值为64.7%,特异度94.3%。
- 淋巴结SUVmax≥4.9使阳性预测值提升至81.1%、灵敏度提升至71.4%。
- 淋巴结SUVmax≥7.2、MRI T≥T3a和miN2是高容量淋巴结病变的预测因素。
核心结论
- 淋巴结SUVmax可提升PSMA-PET/CT对前列腺癌淋巴结分期的阳性预测值,并有助于排除高容量淋巴结病变。
- 整合淋巴结SUVmax与相关临床参数的决策工具具有指导个体化淋巴结管理的潜力。
- 上述发现需在更大队列中进行外部验证。
研究设计与样本
- 国际多中心研究,纳入2016—2023年病理确诊前列腺癌、接受术前PSMA-PET及机器人辅助根治性前列腺切除联合扩大盆腔淋巴结清扫的患者。
- 共纳入521例患者,中位年龄66(61-71)岁,中位PSA 9.9(6.6-17.0)ng/mL。
- 以PROMISE miTNM系统定义非生理性PSMA摄取为阳性,计算灵敏度、特异度、阳性预测值和阴性预测值。
- 采用受试者工作特征曲线分析确定盆腔淋巴结侵犯的最佳淋巴结SUVmax截断值。
- 采用逻辑回归评估病理N1期(pN1)和高容量淋巴结病变(4枚及以上阳性淋巴结)的预测因素,并开发临床决策工具进行三层风险分层。
主要发现
- PSMA-PET检测淋巴结侵犯的灵敏度45.0%、特异度94.3%、阳性预测值64.7%、阴性预测值88.3%。
- 加入淋巴结SUVmax≥4.9后,阳性预测值提升至81.1%,灵敏度提升至71.4%。
- 淋巴结SUVmax≥4.9联合PSA≥10 ng/mL、MRI T分期≥T3a和miT分期≥T3a,可识别高危组中95%的pN1病例。
- 高容量淋巴结病变发生率为3.8%,其中miN0患者中占1.1%。
- 淋巴结SUVmax≥7.2、MRI T分期≥T3a和miN2是多变量分析中高容量淋巴结病变的预测因素,联合用于决策工具可排除所有低风险患者的高容量淋巴结病变。
关键数值与推荐
- 淋巴结侵犯阳性定义为按PROMISE miTNM系统分类的非生理性PSMA摄取。
- 淋巴结SUVmax最佳截断值:盆腔淋巴结侵犯为≥4.9,高容量淋巴结病变为≥7.2。
- 高容量淋巴结病变定义为4枚及以上阳性淋巴结。
- pN1高危组识别标准:淋巴结SUVmax≥4.9联合PSA≥10 ng/mL、MRI T分期≥T3a和miT分期≥T3a。
临床怎么用
- 在PSMA-PET/CT淋巴结分期中纳入淋巴结SUVmax,可提高阳性预测值,减少假阳性。
- 对淋巴结SUVmax≥4.9且合并PSA≥10 ng/mL、MRI T分期≥T3a、miT分期≥T3a的患者,应视为pN1高危人群。
- 淋巴结SUVmax≥7.2、MRI T分期≥T3a和miN2联合评估有助于排除高容量淋巴结病变低风险患者。
局限性
- 研究结论需在更大队列中进行外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate whether nodal maximum standardised uptake value (SUVmax) improves the positive predictive value (PPV) of prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computerised tomography (CT) for detecting lymph node invasion (LNI) in prostate cancer (PCa), and to develop clinical decision tools to guide decision-making for patients with low- and high-volume nodal disease. PATIENTS AND METHODS: This international multicentre study included patients with histopathologically confirmed PCa who underwent preoperative PSMA-PET and robot-assisted radical prostatectomy with extended pelvic lymph node dissection (2016-2023). Sensitivity, specificity, PPV, and negative predictive value (NPV) for LNI detection were calculated, defining a positive test as non-physiological PSMA uptake classified according to the Prostate Cancer Molecular Imaging Standardised Evaluation (PROMISE) molecular imaging Tumour-Node-Metastasis (miTNM) system. Receiver operating curves analysis identified optimal nodal SUVmax cut-offs for pelvic LNI. Logistic regression assessed predictors for pathological N1 stage (pN1) and high-volume nodal disease (four or more positive nodes). Clinical decision tools were developed to stratify patients into three risk groups for pN1 and high-volume nodal disease. RESULTS: A total of 521 patients were included, with a median (interquartile range) age of 66 (61-71) years and prostate-specific antigen (PSA) level of 9.9 (6.6-17.0) ng/mL. The PSMA-PET showed 45.0% sensitivity, 94.3% specificity, 64.7% PPV, and 88.3% NPV for LNI detection. Adding nodal SUVmax ≥4.9 improved the PPV to 81.1% and sensitivity to 71.4% and, combined with a PSA level ≥10 ng/mL, magnetic resonance imaging (MRI) T-stage ≥T3a, and miT-stage ≥T3a, identified 95% of pN1 cases in the high-risk group. High-volume nodal disease was found in 3.8%, including 1.1% in miN0 patients. Nodal SUVmax ≥7.2, MRI T-stage ≥T3a, and miN2 (multiple suspicious LNs) were predictors for high-volume nodal disease and, combined in a clinical decision tool, excluded all low-risk patients for high-volume nodal disease. CONCLUSION: Nodal SUVmax improves PPV of PSMA-PET for nodal staging and aids in excluding high-volume nodal disease. Clinical decision tools integrating nodal SUVmax with relevant clinical parameters demonstrate potential to guide individualised nodal management. These findings warrant external validation in larger cohorts.
引用
- Bruins Slot AS, Sweere V, Heetman JG, et al. Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer. BJU Int. 2026. PMID: 42003684. doi:10.1111/bju.70293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。